TranslateAbout
Bionxt Solutions Inc. (formerly Was Xphy/xphyto Therapeutics Corp. Until 2022-11-11) (CN:BNXT) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 17 2026
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
Feb 17 2026
BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
Feb 5 2026
BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
Jan 26 2026
BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion
Jan 21 2026
BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)
Financials
Revenue
CA$15.82 K
Market Cap
CA$63.69 M
EPS
-0.05
